University of Texas researchers develop CRISPR gene-editing therapy targeting lung tissue to treat cystic fibrosis, correcting 50% of lung stem cells in mice within 10 days.

Researchers at the University of Texas Southwestern Medical Center have developed a CRISPR gene-editing therapy targeting lung tissue to treat cystic fibrosis by correcting genetic mutations. They used lung-targeting lipid nanoparticles carrying CRISPR components to inject mice, with 50% of lung stem cells corrected within 10 days. If successful in humans, the therapy could offer similar lung function to healthy adults.

June 13, 2024
3 Articles

Further Reading